Anti-Inflammatory Enzyme for Pain, Swelling, and Fibrin

Evidence Review

Post-Surgical Swelling: The Landmark Trial

The earliest and most rigorous clinical trial of serrapeptase was published by Tachibana et al. (PMID 6366808) in 1984. This multi-centre, double-blind, placebo-controlled trial enrolled 174 patients undergoing Caldwell-Luc antrotomy — a surgical procedure for chronic sinus empyema — and randomized them to receive serrapeptase or placebo for three days post-operatively. Buccal (cheek) swelling was measured objectively at multiple timepoints up to day five. Patients in the serrapeptase group showed significantly less swelling at every post-operative assessment compared to placebo (p < 0.01 to p < 0.05). This remains one of the better-designed early trials in this area: it used objective measurement, blinding, placebo control, and a reasonable sample size for a surgical endpoint.

Systematic Review: State of the Evidence

Bhagat, Agarwal, and Roy (PMID 23380245) published a comprehensive systematic review in the International Journal of Surgery (2013), identifying 16 clinical trials of serratiopeptidase across PubMed searches, of which 9 were randomized controlled trials. Areas covered included post-surgical inflammation, sinusitis, carpal tunnel syndrome, fibrocystic breast disease, and bronchitis. The review found consistent directional evidence of benefit for inflammation and pain reduction across multiple conditions, with serrapeptase appearing equivalent to diclofenac sodium (a commonly used anti-inflammatory drug) in some acute and chronic inflammation models. However, the review also flagged significant limitations: many studies had small sample sizes, short follow-up, variable dosing with inconsistent reporting, and inadequate statistical power to conclusively establish efficacy. The authors concluded that existing evidence was promising but insufficient to make definitive clinical recommendations — calling for larger, better-designed trials.

Mechanism and Inflammation Resolution

Tiwari (PMID 32104332), published in the Asian Journal of Pharmaceutical Sciences (2017), provides a detailed mechanistic review of how serratiopeptidase interrupts the inflammatory cascade. The paper identifies three primary mechanisms: (1) hydrolysis of bradykinin, histamine, and serotonin, reducing pain signal transmission; (2) degradation of fibrin and debris that accumulate at inflammation sites, facilitating drainage and tissue repair; and (3) thinning of mucus secretions via mucin cleavage in the respiratory tract. The author also notes that serratiopeptidase demonstrates anti-inflammatory activity comparable to NSAIDs in some animal models, while avoiding the prostaglandin pathway that causes gastric irritation. This mechanistic clarity is one of the more compelling aspects of serrapeptase research — even if large human trials are still sparse, the pathways are well-characterized.

Carpal Tunnel Syndrome: Preliminary Trial

Malshe (PMID 11225219), published in the Journal of the Association of Physicians of India (2000), conducted a preliminary (uncontrolled) trial in 20 patients with carpal tunnel syndrome. Patients received 10 mg serratiopeptidase twice daily for six weeks alongside a short initial course of nimesulide (an NSAID). Sixty-five percent of patients showed significant clinical improvement, confirmed by electrophysiological testing — a relatively objective outcome measure for nerve compression. Limitations are substantial: no control group, small n=20, and the concurrent NSAID use confounds attribution. The authors described this as preliminary data warranting a controlled follow-up trial. This study is often cited as evidence for serrapeptase in carpal tunnel, but should be understood as hypothesis-generating rather than confirmatory.

Comprehensive Applications Review

Jadhav et al. (PMID 33134103), published in Biotechnology Reports (2020), reviewed both in vitro and in vivo evidence alongside clinical data across serrapeptase's applications. The paper confirms its anti-inflammatory, fibrinolytic, mucolytic, analgesic, anti-edemic, anti-biofilm, and tissue-permeation-enhancing effects. The authors highlight emerging interest in serrapeptase as an adjunct to antibiotic therapy by disrupting biofilms — though this application remains largely preclinical. They also discuss its potential in cardiovascular settings (dissolving arterial deposits), though human clinical data in this area is largely absent.

Overall Evidence Assessment

Serrapeptase is a pharmacologically coherent compound with well-understood mechanisms and several decades of clinical use in Japan and Europe. The early controlled trials — particularly in post-surgical swelling — are genuinely positive. For sinusitis, carpal tunnel, and joint inflammation, evidence is directionally encouraging but methodologically limited by small trials, short durations, and inconsistent dosing. No serious safety signals have emerged in clinical use at standard doses, and the lack of gastric side effects (compared to NSAIDs) is a practical advantage. The evidence is not yet sufficient to establish it as a first-line treatment for any condition, but for people seeking a well-tolerated adjunct for inflammatory conditions, the risk-benefit profile appears reasonable. Better-powered RCTs are needed to confirm and quantify benefit.